Biotech Startup Incubators Prepare to Cash in on Record VC Funding

Venture capital funding broke records in the biotech industry in 2021. Leading startup incubators from across Europe share their plans to make the most of this trend in 2022, with expectations for big returns and expansion in the works.

In spite of financial volatility resulting from the Covid-19 pandemic, the year 2021 broke records for funding going to life sciences investment firms in Europe. With fresh cash in hand, investors will be increasingly on the lookout for promising biotech startups across Europe.

This trend stands to benefit Europe’s biotech startup incubators, which strive to get their resident companies fuelled beyond the seed stage by venture capital (VC) investments.

The year has been exceptional not only for startups or biotechnology in general, but also in terms of investment in the life sciences industry and the development of existing companies,” said Gediminas Pauliukevičius, Head of Vilnius City Innovation Industrial Park (VCIIP) in Lithuania.

One benefit of the swelling VC spending power for startup incubators is that the startups stand a higher chance of grabbing the attention of VCs and other investors.

The post Biotech Startup Incubators Prepare to Cash in on Record VC Funding appeared first on

© Labiotech UG and Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like